In adults with overweight or obesity, a weekly injection of pemvidutide at 2.4 mg for 48 weeks resulted in nearly half of the participants achieving a body mass index below 30 kg/m², which is the...
Mechanism
Synthesis from 1 study
This drug makes you feel full sooner and helps your liver burn more fat, so you eat less and lose weight. After a year, nearly half the people dropped below the obesity weight threshold because their bodies used more energy than they took in.
Most probable mechanism
The drug activates two receptors in the brain and liver that make you feel full faster and burn more calories, so you eat less and lose weight until your body mass drops below the obesity threshold.
Pemvidutide binds to GLP-1 receptors on hypothalamic neurons, reducing hunger signals and increasing satiety
Pemvidutide simultaneously activates glucagon receptors on hepatocytes, increasing hepatic fat oxidation and energy expenditure
Combined reduction in caloric intake and increase in energy expenditure creates a sustained negative energy balance
Negative energy balance leads to loss of adipose tissue and reduction in body mass index below 30 kg/m²
Evidence from Studies
Supporting (1)
Community contributions welcome
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.